Initial results from BEACON, a phase 1b/2a dose escalation study of the anti-c-Kit briquilimab antibody in adults with chronic spontaneous urticaria (CSU)

被引：0
|
作者：
Casale, Thomas [1 ]
Tucker, Edwin [2 ]
Yuan, Jinwei [2 ]
Adelman, Daniel [3 ]
Ku, David [2 ]
Marcantonio, Annette [2 ]
Carlos, Patricia [2 ]
Majeed, Sophia [2 ]
Pang, Wendy [2 ]
Maurer, Marcus [4 ]
Metz, Martin [5 ]
机构：
[1] Univ S Florida, Tampa, FL USA
[2] Jasper Therapeut, Redwood City, CA USA
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] Charite, Berlin, Germany
[5] Charite Campus Mitte, Berlin, Germany
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2025年 / 155卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
L24
引用
收藏
页码：AB435 / AB435
页数：1
相关论文
共 50 条
  • [21] Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.
    Williamson, Stephen K.
    Hodi, F. Stephen
    Johnson, Melissa Lynne
    Barve, Minal A.
    Juric, Dejan
    Baranda, Joaquina Celebre
    Schneider, Reva Elaine
    Bauer, Todd Michael
    Lin, Tun Tun
    Wang, Rui
    Amrate, Amele
    Guillemin-Paveau, Helene
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
    Wang, Michael
    Nooka, Ajay K.
    Yee, Andrew J.
    Thomas, Sheeba K.
    O'Donnell, Elizabeth
    Shah, Jatin
    Weber, Donna M.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Avigan, David
    Raje, Noopur
    BLOOD, 2014, 124 (21)
  • [23] Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation
    Strati, Paolo
    Kim, Tae Min
    Danilov, Alexey, V
    Cheah, Chan Y.
    Yoon, Dok Hyun
    Jurczak, Wojciech
    Sharma, Shringi
    Yoon, Jeong Lim
    Arduini, Serena
    Saeh, Jamal
    Olsson, Richard F.
    Gregory, Gareth
    BLOOD, 2022, 140 : 6656 - 6658
  • [24] Efficacy and Pharmacokinetic Results From Ongoing Dose Escalation in RESOLVE, a Phase 1b/2a Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis
    Malone, Amanda
    Helliwell, James
    Kowalski, Mark
    Bredenoord, Arjan
    Nguyen, Nam Quoc.
    Ko, Hin Hin
    Dobek, Christine
    Peck, Vik
    Byrne, Catherine
    Dye, Andrew
    Dellon, Evan S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S476 - S477
  • [25] INITIAL RESULTS FROM RESOLVE, AN ONGOING PHASE 1B DOSE-ESCALATION STUDY OF EP-104GI (LONG-ACTING FLUTICASONE PROPIONATE INJECTABLE SUSPENSION) FOR EOSINOPHILIC ESOPHAGITIS
    Helliwell, James
    Malone, Amanda
    Kowalski, Mark M.
    Bredenoord, Arjan
    Ko, Hin Hin
    Nguyen, Nam Q.
    Dobek, Christine
    Peck, Vik
    Dellon, Evan S.
    GASTROENTEROLOGY, 2024, 166 (05) : S414 - S415
  • [26] Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenstrom Macroglobulinemia (WM)
    Siegel, David S.
    Kaufman, Jonathan L.
    Raje, Noopur S.
    Mikhael, Joseph R.
    Kapoor, Prashant
    Treon, Steven P.
    Castillo, Jorge J.
    Neuman, Linda L.
    Lee, Ju RueyJiuan
    Ghobrial, Irene
    BLOOD, 2014, 124 (21)
  • [27] Final results of a multi-center Phase 1b, randomized, placebo-controlled, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
    McHutchison, J. G.
    Bacon, B. R.
    Gordon, S. C.
    Lawitz, E.
    Shiffman, M.
    Afdhal, N. H.
    Jacobson, I. M.
    Muir, A.
    Vicari, A.
    Efler, S.
    Al-Adhami, M.
    Morris, M. L.
    Davis, H. L.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S49 - S49
  • [28] Results from a phase 1b multiple ascending-dose study of PRX002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's Disease
    Jankovic, J.
    Goodman, I.
    Safirstein, B.
    Schenk, D. B.
    Kinney, G. G.
    Koller, M.
    Ness, D. K.
    Griffith, S. G.
    Grundman, M.
    Soto, J.
    Ostrowitzki, S.
    Boess, F. G.
    Martin-Facklam, M.
    Quinn, J. F.
    Isaacson, S. H.
    Jennings, D.
    Omidvar, O.
    Ellenbogen, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 121 - 121
  • [29] Results from a phase 1b multiple ascending-dose study of prx002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease
    Jankovic, J.
    Goodman, I.
    Safirstein, B.
    Schenk, D.
    Kinney, G.
    Koller, M.
    Ness, D.
    Griffith, S.
    Grundman, M.
    Soto, J.
    Ostrowitzki, S.
    Boess, F.
    Martin-Facklam, M.
    Quinn, J.
    Isaacson, S.
    Jennings, D.
    Omidvar, O.
    Ellenbogen, A.
    MOVEMENT DISORDERS, 2017, 32
  • [30] Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).
    Walker, Evan Justin
    Fountzilas, Christos
    Borazanci, Erkut Hasan
    Shields, Anthony F.
    D'Olimpio, James Thomas
    Hecht, J. Randolph
    Tang, Shou-Ching
    Michelson, Glenn
    Liganor, Lorna
    Cho, Sangsook Ahn
    Ko, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 666 - 666
12345